Search Results - "Dhawan, Neil S."

Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma by Tohmé, Rita, Izadmehr, Sudeh, Gandhe, Sai, Tabaro, Giancarlo, Vallabhaneni, Sanjay, Thomas, Ava, Vasireddi, Neal, Dhawan, Neil S, Ma'ayan, Avi, Sharma, Neelesh, Galsky, Matthew D, Ohlmeyer, Michael, Sangodkar, Jaya, Narla, Goutham

“…Although tyrosine kinase inhibitors (TKIs) have demonstrated significant efficacy in advanced lung adenocarcinoma (LUAD) patients with pathogenic alterations…”
Get full text

Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling by Dhawan, Neil S., Scopton, Alex P., Dar, Arvin C.

“…A class of small molecules that stabilize a previously unrecognized inactive state of KSR is reported; the agonists synergize with MEK inhibitors to prevent…”
Get full text

Reengineered tricyclic anti-cancer agents by Kastrinsky, David B., Sangodkar, Jaya, Zaware, Nilesh, Izadmehr, Sudeh, Dhawan, Neil S., Narla, Goutham, Ohlmeyer, Michael

“…[Display omitted] The phenothiazine and dibenzazepine tricyclics are potent neurotropic drugs with a documented but underutilized anti-cancer side effect…”
Get full text

Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response by Sangodkar, Jaya, Dhawan, Neil S, Melville, Heather, Singh, Varan J, Yuan, Eric, Rana, Huma, Izadmehr, Sudeh, Farrington, Caroline, Mazhar, Sahar, Katz, Suzanna, Albano, Tara, Arnovitz, Pearlann, Okrent, Rachel, Ohlmeyer, Michael, Galsky, Matthew, Burstein, David, Zhang, David, Politi, Katerina, Difeo, Analisa, Narla, Goutham

“…EGFR activation is both a key molecular driver of disease progression and the target of a broad class of molecular agents designed to treat advanced cancer…”
Get full text

Corrigendum to “Reengineered tricyclic anti-cancer agents” [Bioorg. Med. Chem. 23 (2015) 6528–6534] by Kastrinsky, David B., Sangodkar, Jaya, Zaware, Nilesh, McClinch, Kimberly, Farrington, Caroline C., Giannini, Heather M., Izadmehr, Sudeh, Dhawan, Neil S., Narla, Goutham, Ohlmeyer, Michael

Get full text

Gene-protein correlation in single cells by Renfrow, Jaclyn J., Scheck, Adrienne C., Dhawan, Neil S., Lukac, Paul J., Vogel, Hannes, Chandler, James P., Raizer, Jeffrey J., Harsh, Griffith R., Chakravarti, Arnab, Bredel, Markus

“…We present a novel methodology combining traditional fluorescent in situ hybridization with an in situ protein detection technology called proximity ligation…”
Get full text

Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth by Sangodkar, Jaya, Perl, Abbey, Tohme, Rita, Kiselar, Janna, Kastrinsky, David B, Zaware, Nilesh, Izadmehr, Sudeh, Mazhar, Sahar, Wiredja, Danica D, O'Connor, Caitlin M, Hoon, Divya, Dhawan, Neil S, Schlatzer, Daniela, Yao, Shen, Leonard, Daniel, Borczuk, Alain C, Gokulrangan, Giridharan, Wang, Lifu, Svenson, Elena, Farrington, Caroline C, Yuan, Eric, Avelar, Rita A, Stachnik, Agnes, Smith, Blake, Gidwani, Vickram, Giannini, Heather M, McQuaid, Daniel, McClinch, Kimberly, Wang, Zhizhi, Levine, Alice C, Sears, Rosalie C, Chen, Edward Y, Duan, Qiaonan, Datt, Manish, Haider, Shozeb, Ma'ayan, Avi, DiFeo, Analisa, Sharma, Neelesh, Galsky, Matthew D, Brautigan, David L, Ioannou, Yiannis A, Xu, Wenqing, Chance, Mark R, Ohlmeyer, Michael, Narla, Goutham

“…Targeted cancer therapies, which act on specific cancer-associated molecular targets, are predominantly inhibitors of oncogenic kinases. While these drugs have…”
Get full text